Skip to main content

MEMBERSHIP BENEFITS (TYPE 1-3)

Leadership

  • Eligibility for appointment as HCI Program Leader (Type 1)
  • Eligibility for appointment as HCI Translational Scholar (Type 1)
  • Eligibility for inclusion in HCI strategic planning (Type 1, 2)
  • Opportunity to provide input on Program and Shared Resource development (Type 1, 2) 

Institutional Funding Opportunities

  • Program Funding
    • Pilot Funding
      • Type 1 and Type 2 members are eligible to serve as Principal Investigators (PIs). Early‑Stage Investigators (as defined by NIH¹) may also serve as PIs; however, applications submitted by Early‑Stage Investigators must include a mentoring component. 
      • Type 3 members are eligible to serve as Co-Is. 
    • Travel Funding (Type 1, 2)
  • Center for Investigational Therapeutics (CIT)
    • Project Funding (Type 1, 2)
  • Team Science Acceleration (TSA) Funding
    • Pilot Research
      • Type 1 and Type 2 members are eligible to serve as PIs or co-investigators
  • Translational Science Initiative (TSI) Funding
    • Pilot Research
      • Type 1 and Type 2 members are eligible to serve as PIs or co-investigators
      • Early-Stage Investigators (as defined by NIH¹) may serve as PIs, but must include a mentoring component 
  • Eligibility to apply for NCI Cancer Center Support Grant (CCSG) Supplement funding (Type 1, 2)
  • Eligibility to apply for American Cancer Society (ACS) Institutional Research Seed Grants (Type 1, 2)
  • Eligibility to apply for HCI-managed limited submission extramural funding opportunities (Types 1-3)

Information and Community

  • Receipt of information regarding external funding opportunities (Types 1-3)
  • Receipt of the HCI newsletter; direct notification of Cancer Center seminars and activities (Types 1-3)
  • Opportunities to interact with cancer research-oriented colleagues via HCI retreats, symposia, seminars, and meetings (All)
  • Opportunities to nominate and host HCI seminar speakers (Types 1-3)
  • Designation as an HCI Investigator (Types 1-3)
  • Eligibility to mentor a post-baccalaureate trainee in the ACS-funded training program (Type 1) 

Scientific and Administrative Support

  • Access to HCI-managed Shared Resources (Types 1-3)
  • Access to interventional clinical research support (Types 1-3) 

MEMBERSHIP RESPONSIBILITIES

Type 1-3 members are expected to:

  • Participate in Cancer Center activities, such as collaborative research projects and/or clinical trials, meetings, seminars, and retreats
  • Respond to requests for information on research progress, ‘other support pages’, publications, extramural funding, trainees, and biosketches with timely and accurate submissions
  • Acknowledge the Cancer Center Support Grant in publications where appropriate2
  • Grant HCI Administration access to funding information provided by PeopleSoft Management Reports 

       1 NIH defines Early-Stage Investigators as researchers who have not yet received a substantial independent research award, and who are within ten years of completing their terminal research degree or the end date of their post-graduate clinical training, whichever is later.

       2 Publications describing research using CCSG-funded shared resources should cite the HCI CCSG award, as follows: "We acknowledge support from [Shared Resource Name] and HCI’s Cancer Center Support Grant." 

Comprehensive Cancer Center Director

Comprehensive Cancer Center Deputy Director

Senior Directors

David Gaffney, MD, PhD
Clinical Research (Interim)
Rachel Ceballos, PhD
Community Outreach and Engagement
Max Loveless, MBA
Senior Administrative Director
Martin McMahon, PhD
Preclinical Translation
Tracy Onega, PhD, MS
Population Sciences
Aik Choon Tan, PhD
Data Science and AI
Katharine Ullman, PhD
Cancer Research Training and Education Coordination
Alana Welm, PhD
Basic Science
David Wetter, PhD, MS
Cancer Health Implementation

Program Leadership

Genomics, Epigenetics, and Metabolism

Jay Gertz, PhD
Co-Leader
Jared Rutter, PhD
Co-Leader

Cancer Biology and Microenvironment 

Shannon Buckley, PhD
Co-Leader
Sheri Holmen, PhD
Co-Leader

Experimental Therapeutics

Howard Colman, MD, PhD
Co-Leader
Martin McMahon, PhD
Co-Leader

Cancer Control and Population Sciences

Jennifer Doherty, MS, PhD
Co-Leader
Kimberly Kaphingst, ScD
Co-Leader